Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Medifast | History Defined

Medifast Just Hit Its 20th 5-Year Low. Are You Smart/Dumb Enough to Buy?

Medifast is a leading provider of weight management products and services. On Wednesday, its stock hit its 20th 5-year low of the past five years. Down 82% over this time, buying its stock at current prices is either a smart or dumb idea. Here’s a look at both sides of…

Balancing Act: Americans Prioritize Daily Self-Care, But Struggle To Keep Up

Survey reveals Americans prioritize daily self-care but struggle to maintain habits

Revealed: The one thing Americans refuse to stop spending on

Revealed: The one thing Americans refuse to stop spending on

A poll of 2,000 US adults found three in four have been affected by inflation, but it isn’t enough for people to compromize one area of their lives

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2022

Wishful Shrinking: Majority Of Americans Who Have Dieted Report No Lasting Change

Almost three in five U.S. adults have attempted a traditional weight-loss diet in their lifetime (58 percent), according to new research.

Medifast: Dividend Insights

Friday marks the last chance for investors to receive the next dividend payout from Medifast (NYSE:MED).

inkl

Read news from The Economist, FT, and more,
with one subscription

Medifast Adopts $100M Accelerated Share Repurchase Program

Medifast Adopts $100M Accelerated Share Repurchase Program

Medifast Inc (NYSE:MED) has entered into an accelerated share repurchase agreement (ASR) with JPMorgan Chase, National Association. Under the agreement, Medifast will repurchase an aggregate of $100 million of its common stock. The buyback equates to about 600,000 shares at the closing price on May 31, 2022, representing 5% of its outstanding stock.…

Medifast Earnings Perspective: Return On Invested Capital

Medifast Earnings Perspective: Return On Invested Capital

According to Benzinga Pro, during Q1, Medifast (NYSE:MED) earned $41.78 million, a 22.8% increase from the preceding quarter. Medifast also posted a total of $417.60 million in sales, a 10.52% increase since Q4.

Recap: Medifast Q1 Earnings

Recap: Medifast Q1 Earnings

Medifast (NYSE:MED) reported its Q1 earnings results on Monday, May 2, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Medifast beat estimated earnings by 0.56%, reporting an EPS of $3.59 versus an estimate of $3.57.

Earnings Outlook For Medifast

Earnings Outlook For Medifast

Medifast (NYSE:MED) is set to give its latest quarterly earnings report on Monday, 2022-05-02. Here's what investors need to know before the announcement. Analysts estimate that Medifast will report an earnings per share (EPS) of $3.56.

Medifast's Ex-Dividend Date Is Monday, Here's What You Need To Know

Medifast's Ex-Dividend Date Is Monday, Here's What You Need To Know

Friday marks the last chance for investors to receive the next dividend payout from Medifast (NYSE:MED).

Medifast: Q4 Earnings Insights

Medifast: Q4 Earnings Insights

Medifast (NYSE:MED) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Medifast beat estimated earnings by 9.81%, reporting an EPS of $2.91 versus an estimate of $2.65.

1

Organisations

Arista Networks

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

396,065 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play